No one knows your symptomatic severe aortic stenosis (SAS) patients like you do.

You have the power to care for these patients with urgency, so patients can get the life-saving treatment they need, when they need it.

Waiting increases the risk of sudden death2

After 6 months that pass without treatment, severe AS patients have over 10% risk of mortality due to complications of their disease.2 With those numbers in mind, you can trust your instincts, act urgently, and ger your patient the treatment they need.

How Many of Your Patients May Be Left Untreated?

Select the estimated number of patients 75 and older you see per week:*

*Based on a 48-week working year. Number calculated from pooled prevalence of all severe aortic stenosis in the elderly (12.4%).3

Key updates from the 2020 ACC/AHA Guidelines for Valvular Heart Disease4

Related to severe symptomatic AS and TAVI

When intervention is considered, patients should be evaluated by a Heart Team (Class 1C-EO)

Engagement between the Heart Team and the primary clinical cardiologist is of critical importance

Recommendations for intervention now focus on age and shared decision making

For 65 to 80 years old, TAVI should be considered, regardless of flow rate (Class IA)

Indications for TAVI are expanding as a result of multiple randomised trials, including the latest PARTNER trials, which are reflected in these recommendations

Patients should be evaluated regularly with examinations and transthoracic echocardiogram (TTE) every year at a minimum

"All patients with severe valvular heart disease being considered for valve intervention should be evaluated by a multidisciplinary team..."

2020 ACC/AHA Guidelines, Top 10 Take-Home Messages

Better outcomes are at the heart of evert Heart Team.

The 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease recommends that all patients with symptomatic severe heart disease be evaluated by a Multidisciplinary Heart Valve Team when intervention is considered.4 Heart Valve Centers can help optimise patient outcomes through improved decision-making and matching of patients to providers with appropriate expertise, experience, and resources.4

The Heart Team depends on your valuable input and your patient benefits as you and the Heart Team collaborate to provide a personalised treatment pathway, from evaluation, imaging, therapy, to follow up. As underscored by the ACC, the Multidisciplinary Heart Valve Team helps present the patient with all appropriate treatment options in a balanced manner, using tools and techniques for shared decision-making in which patient preferences are considered.4 You can feel confident with the informed, guideline-based, multidisciplinary assessment your patient will receive.

Taking a collaborative approach, the Heart Team builds on the foundation of the care you provide your symptomatic SAS patient.

Recommended resources

Sign up to hear from Edwards Lifesciences

Get the information on the latest TAVI data; access to resources; and important updates to you, your staff, and your patients.

References:   1. Carabello BA. Introduction to Aortic Stenosis. Circ. Res 2013;113:179-185. 2. Malaisrie SC, McDonald E, Kruse J, et al. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014;98(5):1564-1571 3. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62(11):1002–1012. 4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Epublished DOI: 10.1016/J.jacc.2020.11.018.